{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477855864
| IUPAC_name = (9''S'')-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9''H'',18''H''-5,21:12,17-di(metheno)dibenzo[''e,k'']pyrrolo[3,4-''h''][1,4,13]oxadiazacyclohexadecine-18,20-dione
| image = Ruboxistaurin.svg
| image2 = Ruboxistaurin 3D ball.png
| alt2 = Ball-and-stick model of the ruboxistaurin molecule
<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| IUPHAR_ligand = 5263
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 169939-94-0
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 153999
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 135727
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 721809WQCP
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 91829

<!--Chemical data-->
| C=28 | H=28 | N=4 | O=3 
| molecular_weight = 468.546 g/mol
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZCBUQCWBWNUWSU-SFHVURJKSA-N
|drug_name=|alt=|caption=|type=|MedlinePlus=|licence_EU=|licence_US=|SMILES=CN(C[C@]1([H])CCN2C=C(C(C(O)=NC3=O)=C3C(C4=CC=CC=C45)=CN5CCO1)C6=CC=CC=C62)C}}
'''Ruboxistaurin''' (proposed brand name '''Arxxant''') is an investigational drug for [[diabetic retinopathy]] being investigated by [[Eli Lilly and Company]].  It is a member of the [[bisindolylmaleimide]] family.

On February 2006, Lilly submitted a [[New Drug Application]] for ruboxistaurin, and on August 18, 2006, Lilly received an "approvable" letter from the [[US FDA]] for ruboxistaurin,<ref>{{cite web |url=http://www.drugs.com/nda/arxxant_060818.html |title=Drugs.com, Eli Lilly and Company Announces Approvable Letter Issued by FDA for Arxxant |accessdate=2008-02-15 |work= }}</ref> with a request for an additional [[clinical trial]], which would take 5 years to complete.<ref>{{cite web |url=http://www.drugs.com/nda/arxxant_060929.html |title=Drugs.com, Lilly Announces FDA Requirement of Additional Clinical Trial Before Ruboxistaurin Could Be Approved for Treatment of Diabetic Retinopathy |accessdate=2008-02-15 |work= }}</ref>
{{update|date=February 2017}}

==Mechanism of action==
Ruboxistaurin is an inhibitor of [[protein kinase C]]-beta.<ref>{{cite journal |vauthors=Clarke M, Dodson PM |title=PKC inhibition and diabetic microvascular complications |journal=Best Pract Res Clin Endocrinol Metab |volume=21 |issue=4 |pages=573â€“86 |date=December 2007 |pmid=18054736 |doi=10.1016/j.beem.2007.09.007}}</ref>

==References==
{{reflist}}

==External links==
*[http://investor.lilly.com/pipeline.cfm Eli Lilly and Company Product Pipeline]

[[Category:Eli Lilly and Company]]
[[Category:Bisindolylmaleimides]]


{{gastrointestinal-drug-stub}}